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Objective: The eﬀect of cinnamon (Cinnamomum Zeylanicum) on serum C-reactive protein (CRP), an acute phase
protein commonly used as a marker of inﬂammation, is uncertain. Therefore, the objective of the present study
was to conduct a systematic review and meta-analysis of published randomised controlled trials (RCTs) of
cinnamon to determine the eﬀect on levels of serum CRP, relative to controls.
Design: Studies were identiﬁed by a search of electronic databases including PubMed, Cochrane Library,
Google Scholar and Scopus before August 2018. Combined and stratiﬁed analyses were used. Weighted mean
diﬀerences (WMD) and its 95% conﬁdence interval were estimated for net change in serum CRP by using
random-eﬀects model. The heterogeneity of meta-analysis was assessed by χ2 and I2 test.
Results: Six studies were identiﬁed, and data from 285 participants were included. Pooled analysis showed
signiﬁcant reductions in serum CRP (WMD:−0.81mg/L, 95% CI:−1.36 to−0.26, p= 0.004), with signiﬁcant
heterogeneity between selected studies. Improvements in sub-group analysis were observed when baseline CRP
levels were greater than 3mg/dL, and in trials of> 12 weeks duration. Doses< 1500mg/day and ≥1500mg/
day were eﬀective in lowering serum CRP (WMD: −0.56 mg/dL, 95% CI: −1.01 to -0.10, p=0.02 and WMD:
−2.13mg/dL, 95% CI: −4.08 to −0.19, p= 0.03), respectively, with signiﬁcantly reduced heterogeneity in
trials with lower doses of cinnamon<1500mg/day (test for heterogeneity: P= 0.22 and I2= 33%). No
changes were found in controls.
Conclusion: Cinnamon supplementation improves levels of serum CRP, particularly in chronic conditions,
where basal CRP levels are raised. Further well-designed studies are warranted to conﬁrm or not the above-
mentioned ﬁndings.
1. Introduction
Cinnamon (Cinnamomum Zeylanicum) belongs to the genus
Cinnamomum of the Lauraceaeis family, derived from the Hebraic and
Arabic term amomon, meaning fragrant spice plant. Comprising over
300 species, it is widely used for its culinary and medicinal properties
with Ceylon and Cassia cinnamon being the most abundant in the U.S
and EU markets.1–3 Cinnamon has attracted much attention due to their
putative health-related properties, which have been ascribed in part to
their polyphenolic content; a diverse group of secondary plant meta-
bolites classiﬁed as phenolic acids, ﬂavonoids, stilbenes and lignans.4
Evidence from experimental studies have shown anti-inﬂammatory and
antioxidative properties, particularly in their ability to reduce reactive
oxygen species (ROS), and improve insulin sensitivity and carbohydrate
metabolism.5–8 Clinical studies also indicate improvement in anthro-
pometric parameters, inﬂammatory mediators, glycemic indices and
lipid proﬁles in patients with type-2 diabetes mellitus (T2DM), non-
alcoholic fatty liver disease and rheumatoid arthritis, and those with a
BMI≥ 27 kg/m2, following cinnamon supplementation.9
C-reactive protein (CRP) is an acute phase protein commonly used
as a marker of inﬂammation, and is associated with early stages of
several chronic conditions including coronary artery disease (CAD),
T2DM, rheumatoid arthritis, pre-diabetes, obesity and nonalcoholic
fatty liver disease.10–13 This increases greatly in inﬂammation processes
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and shows speciﬁc responses in medical conditions such as poly-
cythemia, anemia, and congestive heart failure with no signiﬁcant
changes. However, compared to conventional assessments of in-
ﬂammation factors such as erythrocyte sedimentation rate (ESR) test,
CRP assessment is an ideal indicator in inﬂammations.11,12,14,15 Eﬀects
of cinnamon supplementation on serum CRP level have been in-
vestigated in clinical trial studies. However, evidence from RCTs are
limited and remain inconclusive. Therefore, the aim of the present
study was to conduct a systematic review and meta-analysis to assess
the eﬃcacy of cinnamon supplementation on serum CRP in several
chronic inﬂammatory conditions.
2. Methods and materials
The present meta-analysis was conducted in accordance with
PRISMA (Preferred Reporting Items for Systematic reviews and Meta-
Analysis) requirements for interventional research.16
2.1. Search strategy
Four databases, including Pubmed™, Cochrane Library™, Google
Scholar™ and Scopus™ were used to identify related publications.
Published RCTs were searched from inception to August 2018.
Reference lists from retrieved studies were also manually searched for
additional relevant publications. The following searches in titles, ab-
stracts and keywords: “CRP or C reactive protein” in combination with
“cinnamon” was performed. Studies were included if they followed a
RCT study design with cinnamon supplementation as the intervention.
Those published in English and/or Persian were included in the study.
2.2. Inclusion and exclusion criteria
The inclusion criteria for selected studies were based on the fol-
lowing; RCTs of oral cinnamon supplementation, those with a duration
of more than one week and those reporting mean or median values of
serum CRP levels at baseline and by the end of supplementation in
control and intervention groups with SD, SEM or 95% CI. The exclusion
criteria included duplicated studies, those with no control or placebo
group, those with insuﬃcient data at baseline and/or ﬁnal levels of
serum CRP in control and treatment groups, studies with case-control,
cohort or cross-sectional design, in vitro and animal studies.
2.3. Data extraction
Data were extracted from published studies independently by three
reviewers, and any disagreements were resolved by consensus among
the researchers using the standardised extraction forms to guarantee
accuracy and consistency. The following key data were extracted: year
of publication, country where the intervention was conducted, sample
size of both intervention and control groups, clinical condition of sub-
jects, intervention/placebo details and composition including the do-
sage of cinnamon supplementation (gram or mg per day), treatment
duration and signiﬁcant outcomes. In addition, serum levels of CRP
were reported as mg/dL. For papers containing data in mmol/l, a nu-
merical conversion to mg/dL was carried out based on molecular
weight. Corresponding authors of trials with no reported mean and SD
values for any outcomes of interest were contacted to request their data.
Only the studies providing these data were included in the present
meta-analysis.
2.4. Quality assessment
We performed a systematic assessment of bias in the included study
by using the Cochrane criteria.17 The items used for each included study
assessment were the following ones: adequacy of sequence generation,
the allocation concealment, blinding of participants, personnel and
outcome assessment, the addressing of drop-outs and incomplete out-
come data, selective outcome reporting and other potential sources of
bias. According to the recommendations of the Cochrane Handbook, the
included studies were rated on each of the items as ‘L’ indicating a low
risk of bias, ‘h’ indicating a high risk of bias or ‘u’ when the risk of bias
was unclear.17
2.5. Statistical analysis
The statistical analyses were performed using Review Manager
Software (RevMan 5.3; Cochrane Collaboration, Oxford, England) and
Comprehensive Meta-Analysis (version 3.2; Biostat). The pooled
weighted mean diﬀerence (WMD) and its 95% conﬁdence interval (CI)
were estimated to assess the eﬀects of cinnamon on levels of serum
CRP. The mean and standard deviation (SD) of levels of serum CRP at
baseline and after supplementation in both intervention and control
groups were used. Based on the method of Hozo et al. all reported
median values with their conﬁdence intervals (CI) or their ranges were
converted to mean and SD.18. Existence of heterogeneity and the per-
centage of total variation between studies was assessed by the Co-
chran’s Q-test at P < 0.05 level of signiﬁcance and I2 test (I2 < 50%).
Based on the results (present signiﬁcant heterogeneity with p < 0.05
from χ2 test), a random eﬀ ;ects model was used if I2 > 50% and
P < 0.1. A ﬁxed eﬀects model was used if I2 < 50% and P > 0.1.To
identify the inﬂuence of modulators, pre-deﬁned subgroup analyses
were conducted according to the Cochrane guidelines including treat-
ment duration, dose of intervention, measuring serum CRP/hs-CRP and
baseline CRP level. Sensitivity analysis was performed to estimate the
eﬀects of each trial on the pooled eﬀect size, in which a single trial was
omitted each time and the eﬀect size was re-calculated to assess the
inﬂuence on the overall eﬀect size. In order to examine potential
publication bias, the funnel plot test was performed. If publication bias
exists, the funnel plot shows an asymmetric shape. Additionally, Begg’s
rank correlation test and Egger’s weighted regression test were used to
elucidate possible bias. A P-value<0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Search results and study selection
A ﬂow chart depicting the process of selection and literature search
is presented in Fig. 1. The literature search of electronic databases
identiﬁed 205 potential relevant articles. After removing duplicates
(n= 112), titles and abstracts were screened and sixty-four studies
were excluded, as they were not relevant to our analysis or were not in
English language. A further 23 studies were excluded after further
evaluation due to molecular or animal experiments (n=11), observa-
tional studies (n=2), reviews or editorial papers (n=5), not enough
data for characterisation of subjects or insuﬃcient reporting of baseline
and/or follow-up serum CRP levels in the cinnamon and/or control
group (n= 2), and studies with no control group (n=3). Finally, a
total of 6 RCTs were included in this meta-analysis.
3.2. Description of the studies and quality assessment
All trials were published between 2014 to 2018 and were conducted
in France, India, Iran and the USA.19–24 A total of 285 adult participants
were re-analysed in the study, of which 144 were allocated to receive
cinnamon supplementation and 141 to a control group. Cinnamon do-
sage ranged from 1200mg/day to 3000mg/day, with a median dose of
1850mg/day.19–24 Cinnamon capsules, stick and extracts were the
formulations used in these trials. Duration of supplementation ranged
from 8 weeks to 24 weeks with a median duration of 14 weeks.19–24
Selected studies enrolled patients with non-alcoholic fatty liver disease,
T2DM, metabolic syndrome, obesity, pre-diabetes and rheumatoid
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arthritis.19–24
Baseline level of serum CRP ranged from 1.69mg/dL to 5.74mg/dL
with a median level of 3.76mg/dL in the intervention and 3.75mg/dL
in the control groups, respectively. Five of the 6 studies were conducted
in both males and females, with one study conducted only in female
participants.19–24 All included trials followed a parallel study design.
Three trials evaluated cinnamon in combination with black tea, L-car-
nosine plus chromium guanylate and a multiple dietary supplement
containing cinnamon powder20,23,24 (Table 1). Cinnamon supple-
mentation was apparently safe and well tolerated by participants in all
of the included studies, and no adverse eﬀects were reported.
3.3. Risk of bias assessment
An unclear risk of bias was observed in some of the items including
allocation concealment and other potential sources of bias. However,
most of the included studies were characterized by adequate informa-
tion regarding sequence generation, allocation concealment and
blinding of participants and personnel. The incomplete outcome data
and selective outcome reporting showed a low risk of bias. Details of the
quality of bias assessment are presented in Table 2.
3.4. Pooled estimate of the eﬀect of cinnamon supplementation on serum
CRP
Signiﬁcant reductions in the levels of serum CRP were observed
following cinnamon supplementation in 3 studies.21,23,24 Weighted
mean diﬀerence (WMD) of studies with random eﬀects model analysis
showed a signiﬁcant improvement in serum CRP (WMD: −0.81mg/L,
95% CI: −1.36 to −0.26, p=0.004) with a signiﬁcant heterogeneity
between the included trials (test for heterogeneity: P < 0.0002 and
I2= 79%)(Fig. 2).
3.5. Subgroup analyses
Subgroup analysis was performed to determine the potential source
of heterogeneity, based on study duration, cinnamon dose, serum CRP
and/or high sensitivity CRP (hs-CRP) and baseline CRP following sup-
plementation (Table 3). Results showed that cinnamon supplementa-
tion signiﬁcantly reduced serum CRP levels in participants when the
duration of the study was> 12 weeks (WMD: −0.42mg/L, 95% CI:
−0.65 to -0.20, p=0.0002). The heterogeneity signiﬁcantly decreased
after subgroup analysis by duration of study (test for heterogeneity:
P= 0.96 and I2=0%). Subgroup analysis on studies with cinnamon
doses of< 1500mg/day and ≥1500mg/day also signiﬁcantly inﬂu-
enced levels of serum CRP (WMD: −0.56mg/dL, 95% CI: −1.01 to
−0.10, p=0.02 and WMD: −2.13mg/dL, 95% CI: −4.08 to −0.19,
p=0.03), respectively. There was signiﬁcantly reduced heterogeneity
in studies with lower doses of cinnamon supplementation (test for
heterogeneity: P= 0.22 and I2=33%). Results of subgroup analysis
based on baseline serum CRP also showed that cinnamon supple-
mentation decreased levels of CRP in those with baseline CRP levels of
more than 3mg/dL (WMD: −0.42mg/L, 95% CI: −0.65 to −0.20,
p=0.0002). Moreover, the heterogeneity decreased signiﬁcantly after
subgroup analysis by trials with baseline CRP levels of more than 3mg/
dL.
3.6. Sensitivity analysis
Sensitivity analysis was performed to determine the eﬀect of each
study on the estimated pooled eﬀect size. Results of omitting each study
on the eﬀect size ranged from -0.55mg/L (95% CI=-0.98, -0.11) to
-1.07 mg/L (95% CI=-1.80,-0.35) (Fig. 3).
3.7. Publication bias
The publication bias of this meta-analysis was assessed by ex-
amination of funnel plot. The symmetrical funnel plots suggested that
the selection of publication was not a possible source of bias (Fig. 4).
The absence of publication bias was conﬁrmed by Egger’s linear re-
gression (intercept: −3.9; standard error: 3.82; 95% CI: −5.91, 1.94;
t= 1.4, df= 4; two-tailed p=0.23). Moreover, Begg’s rank correlation
did not highlight any publication bias (Kendall’s Tau with continuity
correction:−-0.4; z= 1.12; two-tailed p= 0.25).
4. Discussion
The present meta-analysis included a total of 285 adults presenting
with non-alcoholic fatty liver disease, T2DM, metabolic syndrome,
obesity, pre-diabetes and rheumatoid arthritis from 6 RCTs. Despite
considerable heterogeneity among the studies, our ﬁndings indicate
improvement in the levels of serum CRP following cinnamon supple-
mentation. To our knowledge, this is the ﬁrst systematic review that has
assessed the eﬀects of cinnamon supplementation on serum CRP.
Signiﬁcant reductions in serum CRP levels by −0.81mg/dL were
observed following cinnamon supplementation with no detectable
changes in the control group. These ﬁndings were consistent across four
of the individual six RCTs assessed in this study.19,21–23. Reductions in
the levels of serum CRP, as observed in the present study, are clinically
important because levels< 1mg/dL are associated with a lower risk of
cardiovascular events, whereas concentrations> 3mg/dL are asso-
ciated with increases in the risk of coronary heart disease up to
58%.25,26
Fig. 1. Meta-analysis Flow Diagram.
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There was signiﬁcant heterogeneity between studies in this meta-
analysis, and subgroup analysis indicated that cinnamon supple-
mentation could lower the levels of serum CRP when the trial duration
was> 12 weeks. Evidence from other meta-analyses assessing the anti-
inﬂammatory properties of complex medicinal herbs (cinnamon, ginger
and other traditional herbs) have also demonstrated signiﬁcant im-
provements in serum CRP levels with study durations exceeding 6 and
10 weeks27–29
Subgroup analysis on studies with cinnamon doses of< 1500mg/
day and ≥1500mg/day found signiﬁcant reductions in the levels of
serum CRP. It therefore seems likely that lower doses are eﬀective and
may be better than using larger doses of cinnamon, which have been
associated with certain adverse eﬀects including diarrhea and head-
ache.30 However, there were no reported adverse eﬀects observed in
the included studies in the present meta-analysis. Similar studies have
also failed to report any adverse eﬀect or reaction following cinnamon
supplementation. Talaei et al. reported beneﬁcial eﬀects of 1000mg/
day cinnamon (Cinnamomum zeylanicum) without side eﬀects,31 and
Tjandrawinata et al. reported a lower risk of hypoglycemic episodes
with no eﬀect on gastrointestinal symptoms.27 Due to the concerns of
potential hepatotoxicity with high doses of coumarin; a naturally oc-
curring volatile oil (benzo-α-pyrone) found in cassia cinnamon (or
Bakers cinnamon), maximum daily limits have been set in the EU based
on the Tolerable Daily Intake (TDI) of 0.1 mg of coumarin per kg
bodyweight per day. It is therefore recommended that no more than
0.5–1 teaspoon (ca. 3–6 g) of cassia cinnamon (or Bakers cinnamon) be
consumed in the diet each day.32 Based on these guidelines a dosage of
1500mg cinnamon as indicated in the present study could theoretically
be ingested safely in the human diet.
Moreover, subgroup analysis based on baseline levels showed that
cinnamon improved serum CRP levels in those with a higher baseline
value (i.e. > 3mg/dL), with heterogeneity decreasing signiﬁcantly
after subgroup analysis. This ﬁnding is in agreement with other studies
in which vitamin E supplementation signiﬁcantly reduced circulating
levels of serum CRP only in those with a baseline value of> 3mg/dL.33
Therefore, the duration of the study and baseline serum CRP levels were
considered to be important and potential sources of observed hetero-
geneity.
CRP, and particularly hs-CRP, is one of the most common and fre-
quently used biomarkers for assessing the inﬂammatory status, with
predictive values for several chronic diseases including CVD.34–42 The
anti-inﬂammatory properties of cinnamon have been reviewed ex-
tensively, and several mechanisms of action have been described.43–47
There are several studies reported beneﬁcial eﬀects of cinnamon and
other nutraceuticals on CRP and blood lipids as well48–51 In vitro and in
vivo studies have reported inhibition of nuclear factor kappa B (NF- κB)
by 2`-hydroxycinnamaldehyde isolated from C. cassia bark,44 and
tumor necrosis factor-α (TNF-α) with extracts of cinnamon in a lipo-
polysaccharide (LPS) model.45 Inhibition of TNF-α genes by cinnamon
water extract via modulation of JNK, p38, ERK1/2 activation and Iκ-Bα
degradation have also been demonstrated.46 Hong et al. reported the
inhibition of the expression of TNF-α by polyphenol-rich cinnamon
water extract (CWE) fraction containing procyanidins, catechin, epi-
catechin and ellagic acid.47 Cinnamon may also downregulate the ex-
pression of various NF-κB-regulated pro-inﬂammatory adipo-cytokines,
(i.e. MCP-1, MCP-4, and eotaxin and interleukins), in addition to
plasminogen activator inhibitor type-1 (PAI-1), through the inhibition
of the transcription factor early growth response (Egr)-1 gene product,
which has been closely linked with insulin resistance and obesity.
Some limitations of this meta-analysis include not controlling for
confounding factors (i.e. dietary intake, physical activity and medica-
tions for several chronic conditions), which may have inﬂuenced our
results. Most of the RCTs included were of a relatively small sample size
to conclude any deﬁnite results, and the characteristics of the study
population were heterogeneous (i.e. patients with non-alcoholic fatty
liver disease, T2DM, metabolic syndrome, obesity, pre-diabetes andTa
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Table 2
Quality of bias assessment of the included trials according to the Cochrane guidelines.
Studies, Year Sequence
Generation
Allocation
Concealment
Blinding of
participants
and personnel
Blinding of outcome
assessment
Incomplete
outcome data
selective outcome
reporting
other potential sources of
bias
Askari;2014 L L L L L L U
Azimi;2015 L L L H L L L
Jain;2017 L U L H L L H
Liu;2015 L U L H L L L
Shishehbor;2018 L L L L L H U
Soare;2014 L U H L L L L
L, low risk of bias; H, high risk of bias; U, unclear risk of bias.
Fig. 2. Forest plots showing the pooled eﬀect size of cinnamon supplementation on serum C-reactive protein (mg/L). Random eﬀects model was used to pool the
mean change of indicators. CI, conﬁdence interval; I-squared inconsistency.
Table 3
Subgroup analysis of cinnamon supplementation on serum CRP level.
Subgroup No WMD (95% CI) Test for overall eﬀect Test for heterogeneity I2(%)
Duration of study, weeks
≤12 weeks 3 −1.37 [-2.86, 0.12] p=0.07 p<0.0001 91
>12 weeks 3 −0.42 [-0.65, -0.20] P= 0.0002 P=0.96 0
Cinnamon dose, mg/day
≥1500mg/d 4 −0.56 [-1.01, -0.10] P= 0.02 P=0.007 76
<1500mg/d 2 −2.13 [-4.08, -0.19] P= 0.03 P=0.22 33
CRP/hsCRP
CRP 2 −0.96 [-2.14, 0.22] P= 0.11 P=0.003 89
hsCRP 4 −0.83 [-1.78, 0.11] P= 0.08 P=0.002 79
Baseline CRP, mg/L
< 3 2 −1.26 [-2.62, 0.10] P= 0.07 P < 0.0001 87
≥3 4 −0.42 [-0.65, -0.20] P= 0.0002 P=0.77 0
*Abbreviations: CRP, C-reactive protein; hsCRP, high-sensitivity C-reactive protein; WMD, weighted mean diﬀerence; CI, conﬁdence interval.
Fig. 3. Sensitivity analysis for the eﬀect of cinnamon supplementation on serum CRP levels.
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rheumatoid arthritis). Despite these limitations, there were several
strengths to this study. Firstly, it is to our knowledge, the ﬁrst time a
systematic review and meta-analysis has been performed in the eva-
luation of cinnamon supplementation on serum CRP levels. A random
eﬀects model was used for assessing heterogeneity between studies, and
RCTs were assessed using subgroup analysis with performed sensitivity
and meta-regression analyses.
5. Conclusion
In conclusion, cinnamon supplementation may exert anti-in-
ﬂammatory properties, as indicated by the reduction in serum hs-CRP
levels. This was particularly evident when basal hs-CRP levels were>
3mg/L, in trials with a duration> 12 weeks, and with dosages of
1500mg/daily. However, due to the limited availability and signiﬁcant
heterogeneity of the available RCTs, conclusions cannot easily be drawn
and further well-designed studies are warranted to conﬁrm these
ﬁndings.
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